Twenty-one cardiothoracic surgical patients have been treated with fibrin as a topical hemostatic/sealing agent, prepared from bovine fibrinogen clotted with bovine thrombin. Serum samples have been collected before treatment with fibrin and postoperatively between 1 and 9 days, 3 and 12 weeks, and 6 and 8 months. The titers of anti-bovine fibrinogen antibodies, measured by ELISA specific for immunoglobulins IgG or IgM, increased to maximal values after about 8 or 6 weeks, respectively. After 8 months, IgG titers were on average 20-fold lower than the mean maximal value, while IgM titers returned to the normal range. IgG was the predominant anti-bovine fibrinogen immunoglobulin as documented by ELISA, affinity chromatography and electrophoresis. Anti-bovine fibrinogen antibodies present in patients reacted readily with bovine fibrinogen, but did not cross-react with human fibrinogen as measured by ELISA or by immunoelectrophoresis. A significant amount of antibodies against bovine thrombin and factor V has been found, many cross-reacting with the human counterparts. No hemorrhagic or thrombotic complications, or clinically significant allergic reactions, occurred in any patient, in spite of antibody presence against some bovine and human coagulation factors. The treatment of patients with bovine fibrin, without induction of immunologic response against human fibrinogen, appeared to be an effective topical hemostatic/sealing measure.
References
1
Bergel S.
Über Wirkung des Fibrins. Deutsch Med Wchschrft 1909; 35: 663
6
Kang SS,
Gosselin C,
Ren D,
Greisler HP.
Selective stimulation of endothelial cell proliferation with inhibition of smooth muscle cell proliferation by fibroblast growth factor-1 plus heparin delivered from fibrin glue suspensions. Surgery 1995; 118: 280-287
8
Strieker RB,
Lane PK,
Leffert JD,
Rodgers GM,
Shuman MA,
Corash L.
Development of antithrombin antibodies following surgery in patients with prosthetic cardiac valves. Blood 1988; 72: 1375-1380
9
Zehnder JL,
Leung LLK.
Development of antibodies to thrombin and factor V with recurrent bleeding in a patient exposed to topical bovine thrombin. Blood 1990; 76: 2011-2016
10
Budzynski AZ,
Marder VJ,
Parker ME,
Shames P,
Brizuela BS,
Olexa SA.
Antigenic markers on fragment DD, a unique plasmic derivative of human crosslinked fibrin. Blood 1979; 54: 794-804
12
Clausen J.
Immunochemical techniques for the determination and estimation of macromolecules. North-Holland Publ Co; Amsterdam, The Netherlands: 1971: 454-465
13
Engvall E.
Enzyme immunoassay ELISA and EMIT. Meth Enzymol 1980; 70: 419-439
15
Pandya BV,
Gabriel JL,
O’Brien J,
Budzynski AZ.
Polymerization site in the β chain of fibrin: Mapping of the Bβ1-55 sequence. Biochemistry 1991; 30: 162-168
16
Fowler WE,
Erickson HP.
Trinodular structure of fibrinogen. Confirmation by both shadowing and negative stain electron microscopy. J Mol Biol 1979; 134: 241-249
19
Ellis SG,
Tcheng JE,
Navetta FI,
Muller DW,
Weisman HF,
Smith C,
Anderson KM,
Califf RM,
Topol EJ.
Safety and antiplatelet effect of murine monoclonal antibody 7E3 Fab directed against platelet glycoprotein IIb/IIIa in patients undergoing elective coronary angioplasty. Coronary Art Dis 1993; 4: 167-175
20
Flaherty MJ,
Henderson R,
Wener MH.
Iatrogenic immunization with bovine thrombin: A mechanism for prolonged thrombin times after surgery. Ann Intern Med 1989; 111: 631-634
23
Rapaport SI,
Zivelin A,
Minow RA,
Hunter CS,
Donnelly K.
Clinical significance of antibodies to bovine and human thrombin and factor V after surgical use of bovine thrombin. Amer J Clin Pathol 1992; 97: 84-91
24
Berruyer M,
Amiral J,
French P,
Belleville J,
Bastien O,
Clerc J,
Kassir A,
Estanove S,
Dechavanne M.
Immunization by bovine thrombin used with fibrin glue during cardiovascular operations. J Thorac Cardiovasc Surg 1993; 105: 892-897
26
Banninger H,
Hardegger T,
Tolber A,
Barth A,
Schupbach P,
Reinhart W,
Lammle B,
Furlan M.
Fibrin glue in surgery: frequent development of inhibitors of bovine thrombin and human factor V. Brit J Haematol 1993; 85: 528-532
28
Berguer R,
Staerkel RL,
Moore EE,
Moore FA,
Galloway WB,
Mockus MB.
Warning: fatal reaction to the use of fibrin glue in deep hepatic wounds. J Trauma 1991; 31: 408-411
31
Sierra DH.
Fibrin sealant adhesive systems: a review of their chemistry, material properties and clinical applications. J Biomat Appl 1993; 7: 309-352
